Shares of Geron Corp. (NASDAQ: GERN), a clinical-stage oncology company, rose by as much as 14.9% in pre-market trading today. The spark? The drugmaker's shares are responding positively to the company's oral presentation over the weekend at the European Hematology Association meeting in Stockholm, Sweden. Specifically, Dr. David Steensma, from the Dana-Farber Cancer Institute, provided an update on the ongoing Part 1 portion of the combined Phase 2/3 trial known as "IMerge" that's assessing the first-in-class telomerase inhibitor, imetelstat, in patients with lower risk myelodysplastic syndromes (MDS). Image source: Getty Images.Continue reading